A powerful platform
Advances in our understanding of disease biology have created a wealth of information about the targets and pathways that play a key role in disease initiation and progression. Curve addresses these targets and pathways by functional screening of a compound library inside a human cell.
Addressing targets in their native environment of a human cell has multiple advantages; for example, the target is presented in all of its dynamic and disease-relevant forms and libraries can be screened on the basis of their biological function.
An evolving platform
Curve’s droplet microfluidic system is the next generation of the Microcycle platform that comprises high efficiency functional screening of a Microcycle library within a single femtolitre liquid droplet. This technology is protected by international patents and patent applications.
The microfluidics platform is being further developed to allow co-encapsulation of mammalian cells with a Microcycle library within these droplets, enabling the discovery of functional hits against membrane proteins in their native conformation. The system is being further developed to screen for functional hits against non-protein targets such as RNA.
A platform built on strong foundations
IP protected
Curve’s proprietary platform is built on pioneering research by the Tavassoli lab and described in more than 30 peer-reviewed publications covering a wide range of protein-protein interactions over a 15-year period. The central components of the Microcycle screening platform are protected through international patents and patent applications and exclusively licensed to Curve.
Promising evolution / Disease area agnostic
Curve’s platform is disease area agnostic and has multiple applications beyond our in-house pipeline. Curve is open to exploring collaborative opportunities with potential partners that have a depth of knowledge in relevant target biology and expertise in drug development.
Pipeline
Curve is deploying its proprietary platform to build a pipeline of first-in-class small molecule drugs against high-priority cancer, immunology and inflammation targets.
Publications
Curve originated from world-leading Microcycle® research conducted by Professor Tavassoli’s academic group in the Department of Chemistry at the University of Southampton, UK.
Vision
Our passion is to transform the lives of patients by developing innovative ways to treat challenging diseases.
